EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Johnson & Johnson's enterprise value is $407,345 Mil.
Johnson & Johnson's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was $24,206 Mil. Therefore, Johnson & Johnson's EV-to-EBITDA for today is 16.83.
The historical rank and industry rank for Johnson & Johnson's EV-to-EBITDA or its related term are showing as below:
JNJ'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 9.62 Med: 15.53 Max: 21.79
Current: 16.83
During the past 13 years, the highest EV-to-EBITDA of Johnson & Johnson was 21.79. The lowest was 9.62. And the median was 15.53.
JNJ's EV-to-EBITDA is ranked worse than 55.83% of 729
companies
in the Drug Manufacturers industry
Industry Median: 14.36
vs JNJ: 16.83
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Johnson & Johnson EV-to-EBITDA Historical Data
The historical data trend for Johnson & Johnson's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Johnson & Johnson's EV-to-EBITDA
For the Drug Manufacturers - General subindustry, Johnson & Johnson's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Johnson & Johnson's EV-to-EBITDA Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Johnson & Johnson's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Johnson & Johnson's EV-to-EBITDA falls into.
Johnson & Johnson's current Enterprise Value is $407,345 Mil.
Johnson & Johnson's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $24,206 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Johnson & Johnson (NYSE:JNJ) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Johnson & Johnson's PE Ratio (TTM) for today is calculated as:
Johnson & Johnson's share price for today is $163.70.
Johnson & Johnson's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $9.350.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Thank you for viewing the detailed overview of Johnson & Johnson's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
JNJ has been successfully added to your 